Expect 65-70% Market Share Over The Next 4-5 Years For Miqnaf Drug: Wockhardt | CNBC TV18

CNBC-TV18 Exclusive | CDSCO approves Wockhardt's oral antibiotic Miqnaf to treat community-acquired bacterial Pneumonia. Speaking to CNBC-TV18, the co's chairman Habil F Khorakiwala says 'Market potential for Miqnaf is around ₹4,000–5,000 cr in India'. He adds, with Miqnaf, revenue potential for co is ₹500-700 cr in the next 2-3 years

#wockhardt #cdsco #miqnafdrug #oralpneumoniaantibiotic #wockhardtgrowthoutlook #cnbctv18 #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday

🔴CNBC TV18 LIVE TV: https://youtube.com/live/P857H4ej-MQ
SUBSCRIBE to our Channel: https://bit.ly/3nvEcxf
---------------------------------------------------------------------------------------------------------------------
👑 Check Out Top CNBC TV18 Playlist Videos:


🔹YoungTurks Reloaded:    • Young Turks Reloaded with Shereen Bhan  

🔹CNBC TV18 Digital Podcast:    • I Did It My Way - CNBC TV18 Digital P...  

🔹Sounding Board:    • Sounding Board | CNBC TV18  

🔹International Videos:    • World News - CNBC-TV18  

🔹CNBC TV18 Market Cafe:    • CNBC TV18 Market Cafe  

🔹CNBC TV18 Digital:    • CNBC-TV18 Digital Videos  

🔹CNBC TV18 Weekend Special:    / playlist